CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Low Dose of KBP-COVID-19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1053 High Dose of KBP-COVID-19 Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-COVID-19 Vaccine in Healthy Seronegative Adults Aged 18-49 and 50-70

This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy CoV-2seronegative adult subjects in 2 age groups, Part A (18-49 years) and Part B (50-70 years).

NCT04473690 Covid19 Biological: Low Dose of KBP-COVID-19 Biological: High Dose of KBP-COVID-19 Biological: Placebo

Primary Outcomes

Description: Occurrence of Adverse Events

Measure: Solicited Administration site reactions

Time: 7 days after vaccination

Description: Occurrence of Adverse Events

Measure: Solicited systemic events

Time: 7 days after vaccination

Secondary Outcomes

Description: Safety Endpoints

Measure: Unsolicited Adverse Events and medically attended adverse events

Time: 43 days after vaccination

Description: Safety Endpoints

Measure: Serious Adverse Events, Medically Attended Adverse Events and New Onset Chronic Diseae

Time: 365 days after vaccination

Description: Immunogenicity

Measure: Vaccine ELISA and neutralizing antibody titers for each treatment group

Time: Baseline, Day 8, 15, 22, 29, 43, 90, 181, 273, 365

Description: Immunogenicity

Measure: Seroconversion rates

Time: Days 8, 15, 22, 29, 43, 90, 181, 273, 365


No related HPO nodes (Using clinical trials)